BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line

Cancer Biology and Therapy

Volumn 11, Issue 5, 2011, Pages 457-463

  Wang, Lin ^a   Park, Paul ^a   Zhang, Huina ^a,b   La Marca, Frank ^a   Claeson, Amy ^b   Valdivia, Juan ^a   Lin, Chia Ying ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

BMP 2; Cancer stem cells; Nanog; Oct3 4; OS99 1; Osteosarcoma; Tumorigenesis

Indexed keywords

ALDEHYDE DEHYDROGENASE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 1; KI 67 ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL SELECTION; CONTROLLED STUDY; DOWN REGULATION; EMBRYONIC STEM CELL; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; UPREGULATION;

ALDEHYDE DEHYDROGENASE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELL LINE, TUMOR; COLLAGEN TYPE I; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; KI-67 ANTIGEN; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OSTEOSARCOMA; SOXB1 TRANSCRIPTION FACTORS;

EID: 79952323440     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.5.14372     Document Type: Article

References (39)

1. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007; 26:1-18. (Pubitemid 46219587)
2. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008; 466:2114-30.
3. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 2008; 26:633-8. (Pubitemid 351264359)
4. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21:2011-8. (Pubitemid 46606391)
5. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-7.
6. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut JA, et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity and impaired dendritic cell transformation capacities. Cancer Res 2000; 60:4403-11. (Pubitemid 32103618)
7. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-84. (Pubitemid 40488633)
8. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005; 7:967-76.
9. Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, Ghivizzani SC, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 2009; 69:5648-55.
10. Wang L, Park P, Lin CY. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 2009; 8:543-52.
11. Wang L, Park P, Zhang H, La Marca F, Lin CY. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 2011; 128:294-303.
12. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996; 10:1580-94. (Pubitemid 26268864)
13. Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P. Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 2010; 66:233-46.
14. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97:105-14. (Pubitemid 41033466)
15. Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 2006; 291:135-45.
16. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 2000; 96:2005-11.
17. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 2004; 316:100-6. (Pubitemid 38299134)
18. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444:761-5. (Pubitemid 44949605)
19. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40:499-507. (Pubitemid 351601215)
20. Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 2007; 31:836-45. (Pubitemid 47165136)
21. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414:105-11.
22. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008; 88:1264-77.
23. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555-67. (Pubitemid 350056407)
24. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8. (Pubitemid 36418143)
25. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-8. (Pubitemid 24067706)
26. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature 2008; 451:345-9.
27. Giuffrida D, Rogers I. Targeting cancer stem cell lines as a new treatment of human cancer. Recent Pat Anticancer Drug Discov 2010; 5:205-18.
28. Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A, et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol 2005; 27:401-7.
29. Orui H, Imaizumi S, Ogino T, Motoyama T. Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: a preliminary report. J Orthop Sci 2000; 5:600-4. (Pubitemid 32016269)
30. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004; 91:151-60.
31. Pouliot F, Blais A, Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 2003; 63:277-81. (Pubitemid 36152479)
32. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Buchler MW, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999; 116:1202-16. (Pubitemid 29203031)
33. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997; 57:5022-7. (Pubitemid 27498113)
34. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005; 26:495-502. (Pubitemid 40246573)
35. Haydon RC, Luu HH, He TC. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 2007; 454:237-46. (Pubitemid 46066041)
36. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994; 127:1755-66. (Pubitemid 24380911)
37. Pera MF, Herszfeld D. Differentiation of human pluripotent teratocarcinoma stem cells induced by bone morphogenetic protein-2. Reprod Fertil Dev 1998; 10:551-5.
38. Yamate J, Kotera T, Kuwamura M, Kotani T. Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines. Exp Toxicol Pathol 2007; 58:299-309. (Pubitemid 46498719)
39. Gillette JM, Gibbs CP, Nielsen-Preiss SM. Establishment and characterization of OS 99-1, a cell line derived from a highly aggressive primary human osteosarcoma. In Vitro Cell Dev Biol Anim 2008; 44:87-95.